Methylguazone, vindesine and cisplatin for the treatment of patients with relapsed or refractory malignant lymphoma

An Eastern Cooperative Oncology Group study (PA482)

Peter H. Wiernik, Vincent Phillips, Fernando J. Camacho, Martin M. Oken, Michael J. O'Connell

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A new regimen not cross-resistant with standard regimens was developed for patients with relapsed or refractory Hodgkin's disease and non-Hodgkin's lymphoma. The regimen consisted of cisplatin, 70 mg/M2 given intravenously on day 1, vindesine, 3 mg/M2 given intravenously on days 1 and 8 (and also on day 15 of the first cycle only), and methylguazone, 600 mg/M2 given intravenously on days 8 and 15. Courses were repeated every 21 days. Thirty-nine patients (35 with non-Hodgkin's and 4 with Hodgkin's lymphoma) were treated and all were evaluable for response and toxicity. There were 5 complete and 14 partial responses for a total response rate of 49% (C.I. = 35%-63%). The median durations of partial and complete response were only 2.8 and 4.2 months, respectively. Only one patient remained in complete response for more than a year. There was one treatment-related death from renal failure on the study. Although this regimen was, in general, well tolerated the results are disappointing and seem no better than those obtained with many other salvage regimens for lymphoma.

Original languageEnglish (US)
Pages (from-to)619-624
Number of pages6
JournalLeukemia and Lymphoma
Volume30
Issue number5-6
StatePublished - Sep 5 1998

Fingerprint

Vindesine
Cisplatin
Lymphoma
Hodgkin Disease
Non-Hodgkin's Lymphoma
Renal Insufficiency
Therapeutics

Keywords

  • Cisplatin
  • Hodgkin's disease
  • Lymphoma
  • Methylguazone
  • Vindesine

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Methylguazone, vindesine and cisplatin for the treatment of patients with relapsed or refractory malignant lymphoma : An Eastern Cooperative Oncology Group study (PA482). / Wiernik, Peter H.; Phillips, Vincent; Camacho, Fernando J.; Oken, Martin M.; O'Connell, Michael J.

In: Leukemia and Lymphoma, Vol. 30, No. 5-6, 05.09.1998, p. 619-624.

Research output: Contribution to journalArticle

@article{39d0de039d1c4980bb7ed57c5b2c1a3b,
title = "Methylguazone, vindesine and cisplatin for the treatment of patients with relapsed or refractory malignant lymphoma: An Eastern Cooperative Oncology Group study (PA482)",
abstract = "A new regimen not cross-resistant with standard regimens was developed for patients with relapsed or refractory Hodgkin's disease and non-Hodgkin's lymphoma. The regimen consisted of cisplatin, 70 mg/M2 given intravenously on day 1, vindesine, 3 mg/M2 given intravenously on days 1 and 8 (and also on day 15 of the first cycle only), and methylguazone, 600 mg/M2 given intravenously on days 8 and 15. Courses were repeated every 21 days. Thirty-nine patients (35 with non-Hodgkin's and 4 with Hodgkin's lymphoma) were treated and all were evaluable for response and toxicity. There were 5 complete and 14 partial responses for a total response rate of 49{\%} (C.I. = 35{\%}-63{\%}). The median durations of partial and complete response were only 2.8 and 4.2 months, respectively. Only one patient remained in complete response for more than a year. There was one treatment-related death from renal failure on the study. Although this regimen was, in general, well tolerated the results are disappointing and seem no better than those obtained with many other salvage regimens for lymphoma.",
keywords = "Cisplatin, Hodgkin's disease, Lymphoma, Methylguazone, Vindesine",
author = "Wiernik, {Peter H.} and Vincent Phillips and Camacho, {Fernando J.} and Oken, {Martin M.} and O'Connell, {Michael J.}",
year = "1998",
month = "9",
day = "5",
language = "English (US)",
volume = "30",
pages = "619--624",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - Methylguazone, vindesine and cisplatin for the treatment of patients with relapsed or refractory malignant lymphoma

T2 - An Eastern Cooperative Oncology Group study (PA482)

AU - Wiernik, Peter H.

AU - Phillips, Vincent

AU - Camacho, Fernando J.

AU - Oken, Martin M.

AU - O'Connell, Michael J.

PY - 1998/9/5

Y1 - 1998/9/5

N2 - A new regimen not cross-resistant with standard regimens was developed for patients with relapsed or refractory Hodgkin's disease and non-Hodgkin's lymphoma. The regimen consisted of cisplatin, 70 mg/M2 given intravenously on day 1, vindesine, 3 mg/M2 given intravenously on days 1 and 8 (and also on day 15 of the first cycle only), and methylguazone, 600 mg/M2 given intravenously on days 8 and 15. Courses were repeated every 21 days. Thirty-nine patients (35 with non-Hodgkin's and 4 with Hodgkin's lymphoma) were treated and all were evaluable for response and toxicity. There were 5 complete and 14 partial responses for a total response rate of 49% (C.I. = 35%-63%). The median durations of partial and complete response were only 2.8 and 4.2 months, respectively. Only one patient remained in complete response for more than a year. There was one treatment-related death from renal failure on the study. Although this regimen was, in general, well tolerated the results are disappointing and seem no better than those obtained with many other salvage regimens for lymphoma.

AB - A new regimen not cross-resistant with standard regimens was developed for patients with relapsed or refractory Hodgkin's disease and non-Hodgkin's lymphoma. The regimen consisted of cisplatin, 70 mg/M2 given intravenously on day 1, vindesine, 3 mg/M2 given intravenously on days 1 and 8 (and also on day 15 of the first cycle only), and methylguazone, 600 mg/M2 given intravenously on days 8 and 15. Courses were repeated every 21 days. Thirty-nine patients (35 with non-Hodgkin's and 4 with Hodgkin's lymphoma) were treated and all were evaluable for response and toxicity. There were 5 complete and 14 partial responses for a total response rate of 49% (C.I. = 35%-63%). The median durations of partial and complete response were only 2.8 and 4.2 months, respectively. Only one patient remained in complete response for more than a year. There was one treatment-related death from renal failure on the study. Although this regimen was, in general, well tolerated the results are disappointing and seem no better than those obtained with many other salvage regimens for lymphoma.

KW - Cisplatin

KW - Hodgkin's disease

KW - Lymphoma

KW - Methylguazone

KW - Vindesine

UR - http://www.scopus.com/inward/record.url?scp=0031873589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031873589&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 619

EP - 624

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5-6

ER -